Hepatocellular carcinoma: Prevalence and molecular pathogenesis of Helicobacter spp.

Future Microbiology

Volumn 4, Issue 10, 2009, Pages 1283-1301

  Tu, Quoc V ^b   Okoli, Arinze S ^a   Kovach, Zsuzsanna ^a   Mendz, George L ^a  

^a UNIVERSITY OF NOTRE DAME   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Enterohepatic; Helicobacter pylori; Helicobacter spp.; Hepatocellular carcinoma; Molecular mechanisms of hepatoma

Indexed keywords

BACTERIAL DNA; CYCLIN D1; CYCLINE; CYTOLETHAL DISTENDING TOXIN; DNA 16S; GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN 70; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE; PROTEIN MDM2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; UVOMORULIN; VASCULOTROPIN;

BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BONE MARROW CELL; CANCER GROWTH; CANCER RISK; DISEASE ASSOCIATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; MIXED INFECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MODELS, BIOLOGICAL; PREVALENCE;

ANIMALIA; BACTERIA (MICROORGANISMS); HELICOBACTER; HELICOBACTER PYLORI;

EID: 74749104454     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.90     Document Type: Review

References (189)

1. Bosch FX, Ribes J, Díaz M, Cléries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 127, S5-S15 (2004).
2. El-Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127(5 Suppl. 1), S27-S34 (2004).
3. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7), 2557-2576 (2007).
4. Makimoto K, Higuchi S: Alcohol consumption as a major risk factor for the rise in liver cancer mortality rates in Japanese men. Int. J. Epidemiol. 28(1), 30-34 (1999).
5. Vecchia Cl: Alcohol and liver cancer. Eur. J. Cancer Prev. 16, 495-497 (2007).
6. Soman NR, Wogan GN: Activation of the c-Ki-ras oncogene in aflatoxin B1-induced hepatocellular carcinoma and adenoma in the rat: detection by denaturing gradient gel electrophoresis. Proc. Natl Acad. Sci. USA 90(5), 2045-2049 (1993).
7. Taddei T, Mistry P, Schilsky ML: Inherited metabolic disease of the liver. Curr. Opin. Gastroenterol. 24(3), 278-286 (2008).
8. Kumagi T, Horiike N, Abe M et al.: Small hepatocellular carcinoma associated with Wilson's disease. Intern. Med. 44(5), 439-443 (2005).
9. Liu CJ, Kao JH: Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors. J. Chin. Med. Assoc. 70(4), 141-145 (2007).
10. Farinati F, Cardin R, Bortolami M et al.: Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. J. Viral Hep. 14(12), 821-829 (2007).
11. Schuppan D, Afdhal NH: Liver cirrhosis. Lancet 371(9615), 838-851 (2008).
12. Ward JM, Anver MR, Haines DC, Benveniste RE: Chronic active hepatitis in mice caused by Helicobacter hepaticus. Am. J. Pathol. 145(4), 959-968 (1994).
13. Ward JM, Benveniste RE, Fox CH, Battles JK, Gonda MA, Tully JG: Autoimmunity in chronic active Helicobacter hepatitis of mice. Serum antibodies and expression of heat shock protein 70 in liver. Am. J. Pathol. 148(2), 509-517 (1996).
14. IARC: Working group on the evaluation of carcinogenic risks to humans Helicobacter pylori. IARC Monogr. Eval. Carcinog. Risks Hum. 61, 220. IARC, Lyon, France (1994).
15. Pellicano R, Menard A, Rizzetto M, Megraud F: Helicobacter species and liver diseases: association or causation? Lancet Infect. Dis. 8(4), 254-260 (2008). ■■ Provides a review of the data correlating molecular markers to serious liver diseases including hepatocellular carcinoma (HCC).
16. Fox JG, Dewhirst FE, Shen Z et al.: Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology 114(4), 755-763 (1998).
17. Coppola N, Stefano GD, Marrocco C et al.: Absence of Helicobacter spp in the liver of patients with primary or metastatic liver cancer. Hepatology 36(5), 1300-1301 (2002).
18. Wadström T, Al-Soud WA, Ljungh Å, Nilsson HO, Stenram U: Absence of Helicobacter species in the liver of patients with primary or metastatic liver cancer. Hepatology 38(2), 532-533 (2003).
19. Wadström T, Abu Al-Soud W, Ljungh A, Nilsson HO, Stenram U: Absence of Helicobacter species in the liver of patients with primary or metastatic liver cancer. Hepatology 38(2), 532-533; author reply 533 (2003).
20. de Magalhães Queiroz DM, Santos A: Isolation of a Helicobacter strain from the human liver. Gastroenterology 121(4), 1023-1024 (2001). ■■ First isolation of a Helicobacter bacteria from diseased human liver.
21. Xuan SY, Li N, Qiang X, Zhou RR, Shi YX, Jiang WJ: Helicobacter infection in hepatocellular carcinoma tissue. World J. Gastroenterol. 12(15), 2335-2340 (2006). ■■ Isolation of Helicobacter pylori bacteria from patient with HCC.
22. Moura SB, Queiroz DM, Rocha GA, Comunian LB, Cara DC: Hepatic changes in mice chronically infected with Helicobacter trogontum. Braz. J. Med. Biol. Res. 36(9), 1209-1213 (2003).
23. Leelawat K, Suksumek N, Leelawat S, Lek-Uthai U: Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients. Southeast Asian J. Trop. Med. Pub. Health 38(5), 881-885 (2007).
24. Abu Al-Soud W, Stenram U, Ljungh A, Tranberg KG, Nilsson HO, Wadstrom T: DNA of Helicobacter spp. and common gut bacteria in primary liver carcinoma. Dig. Liv. Dis. 40(2), 126-131 (2008). ■ Data correlating the presence of Helicobacter DNA to HCC, but not DNA for other common gut bacteria.
25. Ito K, Nakamura M, Toda G, Negishi M, Torii A, Ohno T: Potential role of Helicobacter pylori in hepatocarcinogenesis. Int. J. Mol. Med. 13(2), 221-227 (2004).
26. Itoh M, Wada K, Tan S, Kitano Y, Kai J, Makino I: Antibacterial action of bile acids against Helicobacter pylori and changes in its ultrastructural morphology: effect of unconjugated dihydroxy bile acid. J. Gastroenterol. 34(5), 571-576 (1999).
27. Gunn JS: Mechanisms of bacterial resistance and response to bile Microb. Infect. 2, 907-913 (2000).
28. Okoli AS, Wadström T, Mendz GL: Bioinformatic study of bile responses in Campylobacterales. FEMS Immunol. Med. Microbiol. 49(1), 101-123 (2007). ■ Comprehensive review of the known responses to bile of Helicobacter spp.
29. Verhoef C, Pot RGJ, de Man RA et al.: Detection of identical Helicobacter DNA in the stomach and in the non-cirrhotic liver of patients with hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 15(11), 1171-1174 (2003).
30. Avenaud P, Marais A, Monteiro L et al.: Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma. Cancer 89(7), 1431-1439 (2000). ■ Data correlating the presence of Helicobacter DNA to HCC.
31. Ponzetto A, Pellicano R, Leone N, Berrutti M, Turrini F, Rizzetto M: Helicobacter pylori seroprevalence in cirrhotic patients with hepatitis B virus infection. Nether. J. Med. 56(6), 206-210 (2000). ■ Data on prevalence of H. pylori antibodies in HBV-infected patients.
32. Hänninen ML: Sensitivity of Helicobacter pylori to different bile salts. Eur. J. Clin. Microbiol. Infect. Dis. 10(6), 515-518 (1991).
33. Marshall BJ, Royce H, Annear DI: Original isolation of Campylobacter pyloridis from human gastric mucosa. Microbiol. Lett. 25, 83-88 (1984).
34. Castera L, Pedeboscq A, Rocha M et al.: Relationship between the severity of hepatitis C virus-related liver disease and the presence of Helicobacter species in the liver: a prospective study. World J. Gastroenterol. 12(45), 7278-7284 (2006). ■ Prospective investigation of the presence of Helicobacter DNA and the severity of hepatitis in HCV infections.
35. Fan XG, Zou YY, Wu AH, Li TG, Hu GL, Zhang Z: Seroprevalence of Helicobacter pylori infection in patients with hepatitis B. Br. J. Biomed. Sci. 55(3), 176-178 (1998).
36. Leone N, Pellicano R, Brunello F et al.: Helicobacter pylori seroprevalence in patients with cirrhosis of the liver and hepatocellular carcinoma. Cancer Det. Prev. 27(6), 494-497 (2003). ■ Data on prevalence of H. pylori antibodies in cirrhotic patients with HCC.
37. Pellicano R, Leone N, Berrutti M et al.: Helicobacter pylori seroprevalence in hepatitis C virus positive patients with cirrhosis. J. Hepatol. 33(4), 648-650 (2000).
38. Ponzetto A, Pellicano R, Leone N et al.: Helicobacter infection and cirrhosis in hepatitis C virus carriage: is it an innocent bystander or a troublemaker? Med. Hypo. 54(2), 275-277 (2000).
39. Ponzetto A, Pellicano R, Redaelli A, Rizzetto M, Roffi L: Helicobacter pylori infection in patients with hepatitis C virus positive chronic liver diseases. Microbiologica 26(4), 321-328 (2003).
40. Queiroz D, Rocha A, Rocha G et al.: Association between Helicobacter pylori infection and cirrhosis in patients with chronic hepatitis C virus. Dig. Dis. Sci. 51(2), 370-373 (2006).
41. Spinzi G, Pellicano R, Minoli G et al.: Helicobacter pylori seroprevalence in hepatitis C virus positive patients with cirrhosis. The Como cross-sectional study. Panminerva medica. 43(2), 85-87 (2001).
42. Rocha M, Avenaud P, Menard A et al.: Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut 54(3), 396-401 (2005). ■ Strong correlation of the presence of Helicobacter DNA in tumoral tissue of HCC patients.
43. Blanchard TG, Czinn SJ, Nedrud JG: Host response and vaccine development to Helicobacter pylori infection. Curr. Top. Microbiol. Immunol. 241, 181-213 (1999).
44. Rogers AB, Theve EJ, Feng Y et al.: Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Res. 67(24), 11536-11546 (2007).
45. Peters MG, Terrault NA: Alcohol use and hepatitis C. Hepatology 36(5 Suppl. 1), S220-S225 (2002).
46. Kew MC: Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int. 23, 405-409 (2003).
47. Kew MC: Interaction between hepatitis B and C viruses in hepatocellular carcinogenesis. J. Viral Hepat. 3, 145-149 (2006).
48. Ihrig M, Schrenzel MD, Fox JG: Differential susceptibility to hepatic inflammation and proliferation in AXB recombinant inbred mice chronically infected with Helicobacter hepaticus. Am. J. Pathol. 155(2), 571-582 (1999).
49. Rogers AB, Fox JG: Inflammation and Cancer. I. Rodent models of infectious gastrointestinal and liver cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 286(3), G361-G366 (2004).
50. Tian X-F, Fan X-G, Zhang YAN, Huang YAN, Dai H, Ying R-S: Procuration and identification of bacteria in paraffin-embedded liver tissues of hepatocellular carcinoma by laser-assisted microdissection technique. APMIS 116(1), 10-15 (2008).
51. Diwan BA, Rice JM, Ohshima M, Ward JM: Interstrain differences in susceptibility to liver carcinogenesis initiated by N-nitrosodiethylamine and its promotion by phenobarbital in C57BL/6NCr, C3H/HeNCrMTV- and DBA/2NCr mice Carcinogenesis 7, 215-220 (1986).
52. Weghorst CM, Pereira MA, Klaunig JE: Strain differences in hepatic tumor promotion by phenobarbital in diethylnitrosamine- and dimethylnitrosamine- initiated infant male mice. Carcinogenesis 10, 1409-1412 (1989).
53. Theve EJ, Feng Y, Taghizadeh K et al.: Sex hormone influence on hepatitis in young male A/JCr mice infected with Helicobacter hepaticus. Infect. Immun. 76(9), 1866-1876 (2008).
54. Cortes-Espinosa T, Mondragon-Sanchez R, Hurtado-Andrade H, Sanchez-Cisneros R: Hepatocellular carcinoma and hepatic cirrhosis in Mexico: a 25 year necroscopy review Hepatogastroenterology 44, 1401-1403 (1997).
55. Canella KA, Diwan BA, Gorelick PL et al.: Liver tumorigenesis by Helicobacter hepaticus: considerations of mechanism. In Vivo 10(3), 285-292 (1996). ■ Mechanisms of liver tumorigenesis by Helicobacter hepaticus.
56. Diwan BA, Ward JM, Ramljak D, Anderson LM: Promotion by Helicobacter hepaticus-induced hepatitis of hepatic tumors initiated by N-nitrosodimethylamine in male A/JCr mice. Toxicol. Pathol. 25(6), 597-605 (1997).
57. Sipowicz MA, Chomarat P, Diwan BA et al.: Increased oxidative DNA damage and hepatocyte overexpression of specific cytochrome P450 isoforms in hepatitis of mice infected with Helicobacter hepaticus. Am. J. Pathol. 151, 933-941 (1997).
58. Stout MD, Kissling GE, Suarez FA, Malarkey DE, Ronald AH, Bucher JR: Influence of Helicobacter hepaticus infection on the chronic toxicity and carcinogenicity of triethanolamine in B6C3F1 mice. Toxicol. Pathol. 36(6), 783-794 (2008).
59. Nagamine CM, Rogers AB, Fox JG, Schauer DB: Helicobacter hepaticus promotes azoxymethane-initiated colon tumorigenesis in BALB/c-IL10-deficient mice. Int. J. Cancer 122, 832-838 (2008).
60. Min/+ Mouse. Infect. Immun. 76(6), 2758-2766 (2008).
61. Avenaud P, Le Bail B, Mayo K et al.: Natural history of Helicobacter hepaticus infection in conventional A/J mice, with special reference to liver involvement. Infect. Immun. 71(6), 3667-3672 (2003).
62. Diwan BA, Sipowicz M, Logsdon D et al.: Marked liver tumorigenesis by Helicobacter hepaticus requires perinatal exposure. Environ. Health Perspect. 116(10), 1352-1356 (2008).
63. Madesh M, Benard O, Balasubramanian KA: Glutathione modulates lipid composition of human colon derived HT-29 cells. Int. J. Biochem. Cell Biol. 30(12), 1345-1352 (1998).
64. Luperchio S, Tamir S, Tannenbaum SR: NO-induced oxidative stress and glutathione metabolism in rodent and human cells. Free Radic. Biol. Med. 21, 513-519 (1996).
65. Krishnan N, Doster AR, Duhamel GE, Becker DF: Characterisation of a Helicobacter hepaticus putA mutant strain in host colonization and oxidative stress. Infect. Immun. 76(7), 3037-3044 (2008).
66. Nagata K, Nagata Y, Sato T, Fujino MA, Nakajima K, Tamura T: Serine-, D- and L-proline and alanine as respiratory substrates for Helicobacter pylori: correlation between in vitro and in vivo amino acid levels. Microbiology 149, 2023-2030 (2003).
67. Krishnan N, Becker DF: Oxygen reactivity of PutA from Helicobacter species and proline-linked oxidative stress. J. Bacteriol. 188, 1227-1235 (2006).
68. Hong Y, Wang G, Maier RJ: The NADPH quinone reductase MdaB confers oxidative stress resistance to Helicobacter hepaticus. Microb. Pathog. 44, 169-174 (2008).
69. Hong Y, Wang G, Maier RJ: Helicobacter hepaticus Dps protein plays an important role in protecting DNA from oxidative damage. Free Radic. Res. 40(6), 597-605 (2006).
70. Hong Y, Wang G, Maier RJ: A Helicobacter hepaticus catalase mutant is hypersensitive to oxidative stress and suffers increased DNA damage. J. Med. Microbiol. 56(Pt 4), 557-562 (2007).
71. Singh H, Pandey M, Shukla VK: Salmonella carrier state, chronic bacterial infection and gallbladder carcinogenesis. Eur. J. Cancer Prev. 5(2), 144 (1996).
72. Clayson DB, Mehta R, Iverson F: International Commission for Protection Against Environmental Mutagens and Carcinogens. Oxidative DNA damage - effects of certain genotoxic and operationally non-genotoxic carcinogens. Mut. Res. 317(1), 25-42 (1994).
73. Whary MT, Morgan TJ, Dangler CA, Gaudes KJ, Taylor NS, Fox JG: Chronic active hepatitis induced by Helicobacter hepaticus in the A/JCr mouse is associated with a Th1 cell-mediated immune response. Infect. Immun. 66(7), 3142-3148 (1998).
74. Livingston RS, Myles MH, Livingston BA, Criley JM, Franklin CL: Sex influence on chronic intestinal inflammation in Helicobacter hepaticus-infected A/JCr mice. Comp. Med. 54(3), 301-308 (2004). ■ Describes the type of immune response induced in mice infected with H. hepaticus.
75. Ge Z, Rogers AB, Feng Y et al.: Bacterial cytolethal distending toxin promotes the development of dysplasia in a model of microbially induced hepatocarcinogenesis. Cell. Microbiol. 9(8), 2070-2080 (2007).
76. Lara-Tejero M, Galan JE: A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-like protein. Science 290(5490), 354-357 (2000).
77. Lara-Tejero M, Galan JE: CdtA, CdtB, and CdtC form a tripartite complex that is required for cytolethal distending toxin activity. Infect. Immun. 69(7), 4358-4365 (2001).
78. Lee RB, Hassane DC, Cottle DL, Pickett CL: Interactions of Campylobacter jejuni cytolethal distending toxin subunits CdtA and CdtC with HeLa cells. Infect. Immun. 71(9), 4883-4890 (2003).
79. Pickett CL, Whitehouse CA: The cytolethal distending toxin family. Trends Microbiol. 7(7), 292-297 (1999).
80. Kawabe A, Shimada Y, Uchida S et al.: Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression. Oncology 62(1), 46-54 (2002).
81. Li N, Zhang S-H, Xuan S-Y, Qiang X: Study on Helicobacter infection in liver tissue from hepatocellular carcinoma. Zhonghua Liu Xing Bing Xue Za Zhi 27(10), 894-896 (2006). ■■ Proposed mechanism involving bone marrow-derived stem cells in the development of HCC.
82. Yu CH, Li L, Li YM et al.: Expression of tissue microarray p53, p16 and cyclooxygenase-2 in gastric cancer. Zhonghua Nei Ke Za Zhi 45(8), 658-660 (2006).
83. Chien C-C, Taylor NS, Ge Z, Schauer DB, Young VB, Fox JG: Identification of cdtB homologues and cytolethal distending toxin activity in enterohepatic Helicobacter spp. J. Med. Microbiol. 49(6), 525-534 (2000).
84. Taylor NS, Fox JG, Yan L: In-vitro hepatotoxic factor in Helicobacter hepaticus, H. pylori and other Helicobacter species. J. Med. Microbiol. 42(1), 48-52 (1995). ■ Hepatotoxic factors found in several gastric and enterohepatic Helicobacter spp.
85. Sterzenbach T, Bartonickova L, Behrens W et al.: Role of the Helicobacter hepaticus flagellar sigma factor FliA in gene regulation and murine colonization. J. Bacteriol. 190(19), 6398-6408 (2008).
86. Hynes S, Ferris JA, Szponar B et al.: Comparative chemical and biological characterization of the lipopolysaccharides of gastric and enterohepatic Helicobacters. Helicobacter 9(4), 313-323 (2004).
87. Monteiro MA, Zheng PY, Appelmelk BJ, Perry MB: The lipopolysaccharide of Helicobacter mustelae type strain ATCC 43772 expresses the monofucosyl A type 1 histo-blood group epitope. FEMS Microbiol. Lett. 154(1), 103-109 (1997).
88. Moran AP: Helicobacter pylori lipopolysaccharide-mediated gastric and extragastric pathology. J. Physiol. Pharmacol. 50(5), 787-805 (1999).
89. Keates S, Hitti YS, Upton M, Kelly CP: Helicobacter pylori infection activates NF-κB in gastric epithelial cells. Gastroenterology 113, 1099-1109 (1997).
90. Song X, Tao Y-G, Deng X-Y et al.: Heterodimer formation between c-Jun and Jun B proteins mediated by Epstein-Barr virus encoded latent membrane protein 1. Cell Signal. 16(10), 1153-1162 (2004).
91. Edwards J, Krishna NS, Witton CJ, Bartlett JMS: Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin. Cancer Res. 9(14), 5271-5281 (2003).
92. Frasor J, Danes JM, Komm B, Chang KCN, Lyttle CR, Katzenellenbogen BS: Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144(10), 4562-4574 (2003).
93. Matsui T, Kinoshita T, Morikawa Y et al.: K-Ras mediates cytokine-induced formation of E-cadherin-based adherens junctions during liver development. EMBO J. 21, 1021-1030 (2002).
94. Palmer HG, Sanchez-Carbayo M, Ordonez-Moran P, Larriba MJ, Cordon-Cardo C, Munoz A: Genetic signatures of differentiation induced by 1α,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res. 63(22), 7799-7806 (2003).
95. Selvamurugan N, Kwok S, Partridge NC: Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-β1-stimulated collagenase-3 expression in human breast cancer cells. J. Biol. Chem. 279(26), 27764-27773 (2004).
96. Boutin SR, Rogers AB, Shen Z et al.: Hepatic temporal gene expression profiling in Helicobacter hepaticus-infected A/JCr mice. Toxicol. Pathol. 32(6), 678-693 (2004). ■■ Global analysis of liver gene expression in H. hepaticus-induced HCC in mice.
97. Eppinger M, Baar C, Raddatz G, Huson DH, Schuster SC: Comparative analysis of four Campylobacterales. Nat. Rev. Micro. 2(11), 872-885 (2004).
98. Boutin SR, Shen Z, Rogers AB et al.: Different Helicobacter hepaticus strains with variable genomic content induce various degrees of hepatitis. Infect. Immun. 73(12), 8449-8452 (2005). ■ Correlation of the severity of hepatitis with the genome content of different H. hepaticus strains.
99. tm1Cgn mice. Microbes Infect. 10(7), 726-733 (2008).
100. Erdman SE, Rao VP, Poutahidis T et al.: Nitric oxide and TNF-α trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected Rag2-deficient mice. PNAS 106, 1027-1032 (2009).
101. Suerbaum S, Josenhans C, Sterzenbach T et al.: The complete genome sequence of the carcinogenic bacterium Helicobacter hepaticus. Proc. Natl Acad. Sci. USA 100(13), 7901-7906 (2003).
102. Ge Z, Lee A, Whary MT et al.: Helicobacter hepaticus urease is not required for intestinal colonization but promotes hepatic inflammation in male A/JCr mice. Microb. Pathog. 45(1), 18-24 (2008).
103. Belzer C, van Schendel BAM, Kuipers EJ, Kusters JG, van Vliet AHM: Iron-responsive repression of urease expression in Helicobacter hepaticus is mediated by the transcriptional regulator Fur. Infect. Immun. 72(2), 745-752 (2007).
104. Belzer C, Stoof J, Beckwith CS, Kuipers EJ, Kusters JG, van Vliet AHM: Differential regulation of urease activity in Helicobacter hepaticus and Helicobater pylori. Microbiology 151, 3989-3995 (2005).
105. Schaible UE, Kaufmann SH: A nutritive view on the host-pathogen interplay. Trends Microbiol. 13, 373-380 (2005).
106. Dore MP, Realdi G, Mura D, Graham DY, Sepulveda AR: Helicobacter infection in patients with HCV-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Dig. Dis. Sci. 47(7), 1638-1643 (2002).
107. Huang Y, Fan XG, Wang ZM, Zhou JH, Tian XF, Li N: Identification of Helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J. Clin. Pathol. 57(12), 1273-1277 (2004). ■ Identification of Helicobacter spp. DNA in patients with HCC.
108. Higashi H, Tsutsumi R, Fujita A et al.: Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc. Natl Acad. Sci. USA 99(22), 14428-14433 (2002).
109. Moss SF, Blaser MJ: Mechanisms of disease: inflammation and the origins of cancer. Nat. Clin. Prac. Oncol. 2, 90-97 (2005).
110. Ito KYY, Ota H, El-Zimaity H, Graham DY: Adherence, internalization, and persistence of Helicobacter pylori in hepatocytes. Dig. Dis. Sci. 53(9), 2541-2549 (2008).
111. Hirata Y, Maeda S, Mitsuno Y et al.: Helicobacter pylori activates the cyclin D1 gene through mitogen-activated protein kinase pathway in gastric cancer cells. Infect. Immun. 69(6), 3965-3971 (2001).
112. Zhang YFX, Huang YK, Chen R, Dai H: Helicobacter pylori enhances cyclin D1, PCNA expression in HepG2 cell line. Zhonghua Gan Zang Bing Za Zhi 12(11), 695-696 (2004).
113. Eguchi H, Herschenhous N, Kuzushita N, Moss SF: Helicobacter pylori increases proteasome-mediated degradation of p27kip1 in gastric epithelial cells. Cancer Res. 63(15), 4739-4746 (2003).
114. Shirin H, Sordillo EM, Kolevska TK et al.: Chronic Helicobacter pylori infection induces an apoptosis-resistant phenotype associated with decreased expression of p27kip1. Infect. Immun. 68(9), 5321-5328 (2000).
115. Sommi P, Savio M, Stivala LA et al.: Helicobacter pylori releases a factor(s) inhibiting cell cycle progression of human gastric cell lines by affecting cyclin E/cdk2 kinase activity and Rb protein phosphorylation through enhanced P27KIP1 protein expression. Exp. Cell Res. 281(1), 128-139 (2002).
116. Moldovan GL, Pfander B, Jentsch S: PCNA, the maestro of the replication fork. Cell 129(4), 665-679 (2007).
117. Hu TH, Wang CC, Huang CC et al.: Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol. Rep. 18(6), 1417-1426 (2007).
118. Jorge O, Cuello Carrion FD, Jorge A, Ciocca DR: Helicobacter pylori infection affects the expression of PCNA, p53, c-erbB-2 and Bcl-2 in the human gastric mucosa. Rev. Esp. Enferm. Dig. 95(2), 97-104 (2003).
119. Zhuang XLS, Zheng J, Wang L, Sun G, Li Y: The prognostic research of expression and relationship between Helicobacter pylori of c-met oncogene correlation with gastric mucosal proliferation. Zhonghua Nei Ke Za Zhi 40(6), 381-384 (2001).
120. Keates SKA, Katchar K, Peek RM Jr, Kelly CP: Helicobacter pylori induces up-regulation of the epidermal growth factor receptor in AGS gastric epithelial cells. J. Infect. Dis. 196(1), 95-103 (2007).
121. Kurosawa A MH, Hirose M, Tsune I, Nagahara A, Sato N: Inhibition of cell proliferation and induction of apoptosis by Helicobacter pylori through increased phosphorylated p53, p21 and Bax expression in endothelial cells. J. Med. Microbiol. 51(5), 385-391 (2002).
122. Counter CM, Avilion AA, LeFeuvre CE et al.: Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11(5), 1921-1929 (1992).
123. Hytiroglou P, Theise ND: Telomerase activation in human hepatocarcinogenesis. Am. J. Gastroenterol. 101(4), 839-841 (2006).
124. Oh B-K, Kim H, Park YN et al.: High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab. Invest. 88(2), 144-152 (2007).
125. Satra M, Gatselis N, Iliopoulos D, Zacharoulis D, Dalekos GN, Tsezou A: Real-time quantification of human telomerase reverse transcriptase mRNA in liver tissues from patients with hepatocellular cancer and chronic viral hepatitis. J. Viral Hepat. 14(1), 41-47 (2007).
126. Shimojima M, Komine F, Hisatomi H, Shimizu T, Moriyama M, Arakawa Y: Detection of telomerase activity, telomerase RNA component, and telomerase reverse transcriptase in human hepatocellular carcinoma. Hepatol. Res. 29(1), 31-38 (2004).
127. Qin LF, Ng IOL, Fan ST, Ng M: p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int. J. Cancer 79(4), 424-428 (1998).
128. Zhang GX, Gu YH, Zhao ZQ et al.: Coordinate increase of telomerase activity and c-Myc expression in Helicobacter pylori-associated gastric diseases. World J. Gastroenterol. 10(12), 1759-1762 (2004).
129. Itoh T, Hayashi Y, Kanamaru T et al.: Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 15(4), 422-430 (2000).
130. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB: Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J. Cancer Res. Clin. Oncol. 126(11), 641-646 (2000).
131. Akahane T, Ishii M, Ohtani H, Nagura H, Toyota T: Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer. Liver 18(6), 414-419 (1998).
132. Dubuisson L, Monvoisin A, Nielsen BS, Bail BL, Bioulac-Sage P, Rosenbaum J: Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J. Pathol. 190(2), 190-195 (2000).
133. Iwamoto J-I, Mizokami Y, Takahashi K et al.: Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori. Scand. J. Gastroenterol. 40(7), 783-793 (2005).
134. Tanigawa N, Lu C, Mitsui T, Miura S: Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 26(5), 1216-1223 (1997).
135. Miura H, Miyazaki T, Kuroda M et al.: Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J. Hepatol. 27(5), 854-861 (1997).
136. Torimura T, Sata M, Ueno T et al.: Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum. Pathol. 29(9), 986-991 (1998).
137. Caputo R, Tuccillo C, Manzo BA et al.: Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2- dependent mechanism. Clin. Cancer Res. 9(6), 2015-2021 (2003).
138. Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR: Genetics of hepatocellular carcinoma. World J. Gastroenterol. 13(16), 2271-2282 (2007). ■ Description of genetic characteristics of HCC.
139. Kodama M, Fujioka T, Murakami K et al.: Eradication of Helicobacter pylori reduced the immunohistochemical detection of p53 and MDM2 in gastric mucosa. J. Gastroenterol. Hepatol. 20(6), 941-946 (2005).
140. Kodama M, Murakami K, Sato R, Watanabe K, Fujioka T: Expression of mutant type-p53 products in H. pylori-associated chronic gastritis. World J. Gastroenterol. 13(10), 1541-1546 (2007).
141. Li J-H, Shi X-Z, Lv S, Liu M, Xu G-W: Effect of Helicobacter pylori infection on p53 expression of gastric mucosa and adenocarcinoma with microsatellite instability. World J. Gastroenterol. 11(28), 4363-4366 (2005).
142. Wang J, Chi DS, Kalin GB et al.: Helicobacter pylori infection and oncogene expressions in gastric carcinoma and its precursor lesions. Dig. Dis. Sci. 47(1), 107-113 (2002).
143. Liu Z-F, Chen C-Y, Tang W, Zhang J-Y, Gong Y-Q, Jia J-H: Gene-expression profiles in gastric epithelial cells stimulated with spiral and coccoid Helicobacter pylori. J. Med. Microbiol. 55(8), 1009-1015 (2006).
144. Sipowicz MA, Weghorst CM, Shia YH et al.: Lack of p53 and ras mutations in Helicobacter hepaticus-induced liver tumours in A/JCr mice. Carcinogenesis 18, 233-236 (1997).
145. Kondo S, Shinomura Y, Kanayama S et al.: Helicobacter pylori increases gene expression of hepatocyte growth factor in human gastric mucosa. Biochem. Biophy. Res. Commun. 210(3), 960-965 (1995).
146. Konturek PC, Konturek SJ, Sulekova Z et al.: Expression of hepatocyte growth factor, transforming growth factor α, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer. Aliment. Pharmacol. Ther. 15(7), 989-999 (2001).
147. Suzuki M, Suzuki H, Masaoka T, Tanaka S, Suzuki K, Ishii H: Helicobacter pylori eradication treatment modulates epithelial cell proliferation and tissue content of hepatocyte growth factor in the gastric mucosa. Aliment. Pharmacol. Ther. S1, 158-164 (2004).
148. Backert S, Schwarz T, Miehlke S et al.: Functional analysis of the cag pathogenicity island in Helicobacter pylori isolates from patients with gastritis, peptic ulcer, and gastric cancer. Infect. Immun. 72(2), 1043-1056 (2004).
149. Zhang BY, Chen QY, Fang L, Qian B, Sun GY, Cui HH: Expression of epithelial-cadherin, CD44v6 and connexin43 in hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi 35(10), 616-619 (2006).
150. Chan AO: E-cadherin in gastric cancer. World J. Gastroenterol. 12(2), 199-203 (2006).
151. Chan AO, Peng JZ, Lam SK et al.: Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut 55(4), 463-468 (2006).
152. Fan XG, Fan XJ, Xia HX, Keeling PW, Kelleher D: Up-regulation of CD44 and ICAM-1 expression on gastric epithelial cells by Helicobacter pylori. APMIS 103(10), 744-748 (1995).
153. Higuchi K, Arakawa T, Uchida T et al.: In situ expression of cell adhesion molecules in chronic gastritis with Helicobacter pylori infection. J. Gastroenterol. S1, S215-S221 (1997).
154. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM et al.: Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 6961, 968-973 (2003).
155. Alison M: Liver stem cells. Stem Cell Rev. 1(3), 253-260 (2005).
156. Houghton J, Stoicov C, Nomura S et al.: Gastric cancer originating from bone marrow-derived cells. Science 306(5701), 1568-1571 (2004).
157. Masumoto A, Arao S, Otsuki M: Role of β-1 integrins in adhesion and invasion of hepatocellular carcinoma cells. Hepatology 29(1), 68-74 (1999).
158. Lub M, van Kooyk Y, van Vliet SJ, Figdor CG: Dual role of the actin cytoskeleton in regulating cell adhesion mediated by the integrin lymphocyte function-associated molecule-1. Mol. Biol. Cell. 8(2), 341-351 (1997).
159. Zhang Y, Fan XG, Chen R et al.: Comparative proteome ana lysis of untreated and Helicobacter pylori-treated HepG2. World J. Gastroenterol. 14, 3485-3489 (2005).
160. Yanagisawa N, Geironson L, Al-Soud WA, Ljungh S: Expression of matrix metalloprotease-2,-7 and -9 on human colon, liver and bile duct cell lines by enteric and gastric Helicobacter species. FEMS Immuno. Med. Microbiol. 44(2), 197-204 (2005).
161. Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE: Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 43(6), 791-797 (1998).
162. Okoli AS, Fox EM, Raftery MJ, Mendz GL: Effects of Helicobacter hepaticus on the proteome of HEp-2 cells. Antonie Van Leeuwenhoek 92(3), 289-300 (2007).
163. Meyer K, Lee J-S, Dyck PA et al.: Molecular profiling of hepatocellular carcinomas developing spontaneously in acyl-CoA oxidase deficient mice: comparison with liver tumors induced in wild-type mice by a peroxisome proliferator and a genotoxic carcinogen. Carcinogenesis 24(5), 975-984 (2003).
164. Bartsch S, Tschesche H: Cloning and expression of human neutrophil lipocalin cDNA derived from bone marrow and ovarian cancer cells. FEBS Lett. 357(3), 255-259 (1995).
165. Bratt T: Lipocalins and cancer. Biochim. Biophys. 1482(1-2), 318-326 (2000).
166. Furutani M, Arii S, Mizumoto M, Kato M, Imamura M: Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett. 122(1), 209-214 (1998).
167. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L: Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 38(3), 414-420 (1996).
168. Hatanaka E, Pereira Ribeiro F, Campa A: The acute phase protein serum amyloid A primes neutrophils. FEMS Immunol. Med. Microbiol. 38(1), 81-84 (2003).
169. Ribeiro FP, Furlaneto CJ, Hatanaka E et al.: mRNA expression and release of interleukin-8 induced by serum amyloid A in neutrophils and monocytes. Mediators Inflamm. 12(3), 173-178 (2003).
170. Xuan SY, Xin YN, Chen AJ et al.: Association between the presence of H. pylori in the liver and hepatocellular carcinoma: a meta -ana lysis. World J. Gastroenterol. 14, 307-312 (2008). ■ Meta-analysis of the potential association between the presence of H. pylori in the liver and HCC.
171. Pandey M, Shukla M: Helicobacter species are associated with possible increase in risk of hepatobiliary tract cancers. Surg. Oncol. 18(1), 51-56 (2009).
172. Shukla VK, Singh H, Pandey M, Upadhyay SK, Nath G: Carcinoma of the gallbladder - is it a sequel of typhoid? Dig. Dis. Sci. 45(5), 900-903 (2000).
173. Singh H, Pandey M, Shukla VK: Salmonella carrier state, chronic bacterial infection and gallbladder carcinogenesis. Eur. J. Cancer Prev. 5(2), 144 (1996).
174. Leelawat K, Suksumek N, Leelawat S, Lek-Uthai U. Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients. Southeast Asian J. Trop. Med. Public Health 38(5), 881-885 (2007).
175. Xuan SY, Li N, Qiang X, Zhou RR, Shi YX, Jiang WJ: Helicobacter infection in hepatocellular carcinoma tissue. World J. Gastroenterol. 12, 2335-2340 (2006).
176. Brogden KA, Roth JA, Stanton TB, Bolin CA, Minion FC, Wannemuehler MJ: Virulence Mechanisms of Bacterial Pathogens (3rd Edition). ASM Press, WA, USA (2000).
177. Seeff LB. Natural history of chronic hepatitis C. Hepatology 36(5 Suppl. 1), S35-S46 (2002).
178. Fox JG, Drolet R, Higgins R et al.: Helicobacter canis isolated from a dog liver with multifocal necrotizing hepatitis. J. Clin. Microbiol. 34(10), 2479-2482 (1996).
179. Boomkens SY, Kusters JG, Hoffmann G et al.: Detection of Helicobacter pylori in bile of cats. FEMS Immunol. Med. Microbiol. 42(3), 307-311 (2004).
180. Fox JG, Dewhirst FE, Tully JG et al.: Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. J. Clin. Microbiol. 32(5), 1238-1245 (1994).
181. Fox JG, Rogers AB, Whary MT et al.: Helicobacter bilis-associated hepatitis in outbred mice. Comp. Med. 54(5), 571-577 (2004).
182. Fox JG, Handt L, Sheppard BJ et al.: Isolation of Helicobacter cinaedi from the colon, liver, and mesenteric lymph node of a rhesus monkey with chronic colitis and hepatitis. J. Clin. Microbiol. 39(4), 1580-1585 (2001).
183. Fox JG, Shen Z, Xu S et al.: Helicobacter marmotae sp. nov. isolated from livers of woodchucks and intestines of cats. J. Clin. Microbiol. 40(7), 2513-2519 (2002).
184. Shen Z, Xu S, Dewhirst FE et al.: A novel enterohepatic Helicobacter species 'Helicobacter mastomyrinus' isolated from the liver and intestine of rodents. Helicobacter 10(1), 59-70 (2005).
185. Franklin CL, Beckwith CS, Livingston RS et al.: Isolation of a novel Helicobacter species, Helicobacter cholecystus sp. nov., from the gallbladders of Syrian hamsters with cholangiofibrosis and centrilobular pancreatitis. J. Clin. Microbiol. 34(12), 2952-2958 (1996).
186. Garcia A, Xu S, Dewhirst FE, Nambiar PR, Fox JG: Enterohepatic Helicobacter species isolated from the ileum, liver and colon of a baboon with pancreatic islet amyloidosis. J. Med. Microbiol. 55(11), 1591-1595 (2006).
187. Fan XG, Peng XN, Huang Y, Yakoob J, Wang ZM, Chen YP: Helicobacter species ribosomal DNA recovered from the liver tissue of Chinese patients with primary hepatocellular carcinoma. Clin. Infec. Dis. 35(12), 1555-1557 (2002). ■ Isolation of Helicobacter spp. ribosomal DNA from patients with HCC.
188. Pellicano R, Mazzaferro V, Grigioni WF et al.: Helicobacter species sequences in liver samples from patients with and without hepatocellular carcinoma. World J. Gastroenterol. 10(4), 598-601 (2004).
189. Nilsson HO, Mulchandani R, Tranberg KG, Stenram U, Wadstrom T: Helicobacter species identified in liver from patients with cholangiocarcinoma and hepatocellular carcinoma. Gastroenterology 120(1), 323-324 (2001).